A Phase-1, Single Center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics (Including Food Effect) of Ascending Oral Doses of AZD5847 in Healthy Male Subjects and Female Subjects of Non-childbearing Potential
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Posizolid (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors AstraZeneca
- 13 Jul 2010 Additional trial identifier D3430C00001 identified as reported by ClinicalTrials.gov.
- 13 Jul 2010 Additional lead trial centre, investigator identified as reported by ClinicalTrials.gov.
- 13 Jul 2010 Actual patient number (64) added as reported by ClinicalTrials.gov.